September 30, 2025

Long COVID &  Periods: What's the Link?

Researchers examine menstrual changes and immune patterns in patients with long COVID.

Conexiant

September 23, 2025

Autism Briefing Without CDC Input?

Debate over acetaminophen use in pregnancy and vaccine safety highlights the importance of evidence-based guidance for autism risk counseling.

KFF Health News

October 28, 2024

Single Swab Approach Assesses Co-Occurring Vaginal Infections

A recent study reveals that 80% of women with STIs may have bacterial vaginosis, highlighting the potential benefits of simultaneous STI and vaginitis testing in clinical practice.

Conexiant

March 03, 2025

HCV Screening Uptake in Pregnancy vs General Population

Researchers found that universal hepatitis C screening guidelines increased testing rates in pregnant women, but overall uptake remained low, particularly among nonpregnant women.

Conexiant

April 29, 2025

Flu Shots Linked to Temporary Menstrual Changes

Study shows small, temporary cycle length increases after vaccination

Conexiant

November 19, 2024

Does Tetracycline Use in Pregnancy Affect Birth Defects?

A recent study in the Swedish population found no increased risk of major congenital malformations associated with tetracycline use during the first trimester of pregnancy. Further research may help clarify potential risks for specific malformation subgroups.

Conexiant

June 24, 2025

Exam Shift Spurs National Rights Battle

Democratic AGs push to relocate OB-GYN exams from Texas, citing threats to reproductive and gender-affirming care under state abortion bans.

KFF Health News

May 20, 2025

STIs Associated with Bacterial Vaginosis Recurrence

Large retrospective study finds gonorrhea infection significantly increases bacterial vaginosis recurrence odds by up to 549%.

Conexiant

March 25, 2025

New Oral Antibiotic Targets Uncomplicated UTIs

FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.

Conexiant